PureTech Health PLC PRTC's resTORbio Files Public S1 for NASDAQ IPO

TIDMPRTC

PureTech Health PLC

02 January 2018

2 January 2018

PureTech Health plc

PureTech Health Affiliate resTORbio Files Public Registration Statement for Proposed Initial Public Offering

PureTech Health plc (LSE: PRTC) announced that resTORbio, Inc., an affiliate of PureTech Health, has filed a public registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. resTORbio intends to list its common stock under the symbol "TORC" on The Nasdaq Global Market.

BofA Merrill Lynch, Leerink Partners and Evercore ISI are acting as joint lead book-running managers for the proposed offering. Wedbush PacGrow is acting as co-manager.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained by visiting the SEC's website at www.sec.gov or by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or by email at [e-mail]; Leerink Partners, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at [phone] extension 6132 or by email at [e-mail]; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at [phone], or by email at [e-mail].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About resTORbio

resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio's lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging. resTORbio's lead product candidate, RTB101, alone or in combination with everolimus, is in a Phase 2b clinical trial to evaluate its potential in reducing the incidence of respiratory tract infections (RTI) in elderly subjects.

Contact:

 
   PureTech Health:          Investor Relations: 
   Allison Mead Talbot       FTI Consulting 
    [phone]           Ben Atwell, Rob 
    [e-mail]    Winder 
                              [phone] 
                              1000 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADDGDBDBGBGIB

(END) Dow Jones Newswires

January 02, 2018 02:00 ET (07:00 GMT)